OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet Rheumatology is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Molecular signature-based decision making in the era of targeted therapies for systemic lupus erythematosus	951
Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease	904
Brachial plexopathy: an unusual manifestation of Takayasu arteritis	324
Thrombotic microangiopathy as a presentation of anti-synthetase syndrome	201
A disseminated gonococcal infection with spinal locations	189
Research in Brief	133
Dual JAK and ROCK inhibition with CPL'116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial	133
Reigniting the burnt-out health-care workforce	120
Women in rheumatology in Africa	118
Biological disease-modification in axial spondyloarthritis: insights from MRI	114
Pathways driving tendinopathy and enthesitis: siblings or distant cousins in musculoskeletal medicine?	110
Three-dimensional, in-vitro approaches for modelling soft-tissue joint diseases	104
Can contextual factors improve clarity of the results from clinical trials of low back pain?	87
COVID-19 vaccine-induced T-cell responses in patients with rheumatoid arthritis: preferential induction by ChAdOx1	83
From phenotype to pathophysiology—placing rheumatic diseases in an immunological perspective	76
Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study	72
Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries	70
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial	68
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?	62
Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands	61
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial	58
Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica due to lumbar disc herniation	58
Interleukin-5 inhibition in eosinophilic granulomatosis with polyangiitis: time for another approach?	56
Early-stage Dupuytren's disease treatment; a promising next step?	54
Juvenile systemic lupus erythematosus presenting as retinal vasculitis	49

The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study	47
Research in Brief	46
Reclassifying ANCA-associated vasculitis: a focus on kidney disease	46
Immunity after COVID-19 vaccinations in immunocompromised patients with psoriasis	45
Outdoor temperatures and Raynaud's phenomenon in patients with systemic sclerosis	45
Composite endpoints for Sjögren's Syndrome	45
Assessing glucocorticoid toxicity: are the measures sensitive enough?	44
Patient-reported outcomes with anifrolumab in patients with systemic lupus erythematosus	44
Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial	44
Sex as a predictor of clinical phenotype and determinant of immune response in IgG4-related disease: a retrospective study of patients fulfilling the American College of Rheumatology–European League A	43
Preload deficiency as a treatable cause of fatigue and exercise intolerance in SLE	43
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study	43
Proof-of-concept studies in axial spondyloarthritis: there are no shortcuts	42
First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort study	42
Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus	42
Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis	41